主页 > 医学信息 >
【商业翻译】（医师报约稿）Finasteride Improves T
2.本星期三（5.16）晚上十点前交稿
3.格式见置顶的文摘编译格式：http://www.dxy.cn/bbs/post/view?bid=116&id=8600034&sty=1&tpg=1&age=0
4.稿酬按医师报标准
5.为保证翻译质量起见，在本版得分超过15分以上的战友方可认领
6.每位战友最多认领2篇,编译群战友可根据自己的专业和精力，最多认领3篇
7.作者统一署名为"丁香"
8.质量第一，切切
"
Finasteride Improves The Sensitivity Of Digital Rectal Examination For Prostate Cancer Detection
UroToday.com- In the May, 2007 issue of the Journal of Urology, Dr. Ian Thompson and associates report that finasteride improves prostate cancer (CaP) detection with digital rectal examination (DRE). The authors hypothesized that finasteride would improve the detection of CaP by shrinking the prostate and resulting in a more sensitive DRE. They performed their study using the Prostate Cancer Prevention Trial database. The seven year study randomized men to finasteride 5mg daily or placebo and follow-up included prostate biopsies in those with increases in PSA or an abnormal DRE.
After exclusions, 4,579 participants in the finasteride arm, including 873 with biopsy for PSA >4.0ng/mlor abnormal DRE and 3,706 without either indication, and 5,112 in the placebo arm, including 1,012 with biopsy for increased PSA or abnormal DRE and 4,100 without either indication, were available for analysis. Indications for biopsy were usually either an elevated PSA or abnormal DRE, but rarely both. Increased PSA led to diagnosis of CaP in 33% of men on finasteride and 24% on placebo. In the 15.2% in the finasteride arm with the diagnosis of CaP, tumor grade was available in 686; Gleason 7 or higher occurred in 264 and Gleason 8 or higher in 81 men. In the 21.7% in the placebo arm diagnosed with CaP, tumor grade was available in 1,111; Gleason 7 or higher occurred in 240 and Gleason 8 or higher in 55 men.
DRE sensitivity was significantly higher for detecting CaP in men on finasteride compared to placebo (21.3% vs. 16.7%). A trend for increased DRE detection in high grade disease for those on finasteride existed as well, although it did not reach statistical significance. DRE specificity exceeded 90% in the two groups and was not different between the groups. DRE performed better for high-grade disease than for cancer overall in each group. Regardless of PSA level, DRE sensitivity for CaP detection was better in men on finasteride.
Thompson IM, Tangen CM, Goodman PJ, Lucia MS, Parnes HL, Lippman SM, Coltman Jr. CA
J Urol 2007; 177(5): 1749-52
Reviewed by UroToday.com Contributing Editor Christopher P. Evans, MD 原文见： J Urol 2007; 177(5): 1749-52
Finasteride Improves The Sensitivity Of Digital Rectal Examination For Prostate Cancer Detection
非那雄胺提高直肠指检诊断前列腺癌的灵敏度
UroToday.com- In the May, 2007 issue of the Journal of Urology, Dr. Ian Thompson and associates report that finasteride improves prostate cancer (CaP) detection with digital rectal examination (DRE). The authors hypothesized that finasteride would improve the detection of CaP by shrinking the prostate and resulting in a more sensitive DRE. They performed their study using the Prostate Cancer Prevention Trial database. The seven year study randomized men to finasteride 5mg daily or placebo and follow-up included prostate biopsies in those with increases in PSA or an abnormal DRE.
泌尿专题新闻网站-《泌尿学杂志》2007年5月刊上Ian Thompson 博士及其同事报道了非那雄胺改善了直肠指检（DRE）诊断前列腺癌（CaP）。作者假设非那雄胺通过使前列腺缩小导致DRE灵敏度更高，从而改善CaP的诊断。他们应用前列腺预防试验资料进行研究。这项长达7年研究中，参与者随机服用非那雄胺5mg/日或安慰剂，随访包括对PSA升高或DRE异常的参与者行前列腺活检。
After exclusions, 4,579 participants in the finasteride arm, including 873 with biopsy for PSA >4.0ng/mlor abnormal DRE and 3,706 without either indication, and 5,112 in the placebo arm, including 1,012 with biopsy for increased PSA or abnormal DRE and 4,100 without either indication, were available for analysis. Indications for biopsy were usually either an elevated PSA or abnormal DRE, but rarely both. Increased PSA led to diagnosis of CaP in 33% of men on finasteride and 24% on placebo. In the 15.2% in the finasteride arm with the diagnosis of CaP, tumor grade was available in 686; Gleason 7 or higher occurred in 264 and Gleason 8 or higher in 81 men. In the 21.7% in the placebo arm diagnosed with CaP, tumor grade was available in 1,111; Gleason 7 or higher occurred in 240 and Gleason 8 or higher in 55 men.
不符合条件的排除之后，参与者中非那雄胺组4,579例（873例因PSA >4.0ng/ml或DRE异常而行活检、 3706无PSA升高或DRE异常未行活检）、安慰剂组5112 例（1,012例因PSA 升高或DRE异常而行活检、4100 无PSA升高或DRE异常未行活检）可用来进行分析。活检指征常常是PSA升高或DRE异常，而两项同时存在的极少。非那雄胺组有33%男性因PSA升高而诊断CaP、安慰剂组为24%。非那雄胺组15.2%诊断为CaP，686例有肿瘤分级，Gleason≥7有264例、Gleason≥8有81例;安慰剂组21.7%诊断为CaP，1111例有肿瘤分级，Gleason≥7有240例、Gleason≥8有55例.
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-06-01 14:37
医学,生命科学网